CN102076326B - 治疗多发性硬化的组合物和方法 - Google Patents

治疗多发性硬化的组合物和方法 Download PDF

Info

Publication number
CN102076326B
CN102076326B CN200980124930.5A CN200980124930A CN102076326B CN 102076326 B CN102076326 B CN 102076326B CN 200980124930 A CN200980124930 A CN 200980124930A CN 102076326 B CN102076326 B CN 102076326B
Authority
CN
China
Prior art keywords
oxygen
use according
fluid
ppm
rotor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980124930.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102076326A (zh
Inventor
理查德·L·华森
安东尼·B·伍德
格雷戈里·J·阿咸宾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdiffusion Inc
Original Assignee
Microdiffusion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/256,774 external-priority patent/US20090227018A1/en
Priority claimed from PCT/US2008/081021 external-priority patent/WO2009055614A1/en
Application filed by Microdiffusion Inc filed Critical Microdiffusion Inc
Publication of CN102076326A publication Critical patent/CN102076326A/zh
Application granted granted Critical
Publication of CN102076326B publication Critical patent/CN102076326B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN200980124930.5A 2008-04-28 2009-04-27 治疗多发性硬化的组合物和方法 Active CN102076326B (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US4833208P 2008-04-28 2008-04-28
US4834708P 2008-04-28 2008-04-28
US61/048,347 2008-04-28
US61/048,332 2008-04-28
USPCT/US2008/081021 2008-10-23
US12/256,774 2008-10-23
US12/256,774 US20090227018A1 (en) 2007-10-25 2008-10-23 Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
PCT/US2008/081021 WO2009055614A1 (en) 2007-10-25 2008-10-23 Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US12/258,210 2008-10-24
US12/258,210 US20090274730A1 (en) 2007-10-25 2008-10-24 Compositions and methods for treating inflammation
PCT/US2008/081202 WO2009055729A1 (en) 2007-10-25 2008-10-24 Compositions and methods for treating inflammation
USPCT/US2008/081202 2008-10-24
PCT/US2009/041852 WO2009134728A2 (en) 2008-04-28 2009-04-27 Compositions and methods for treating multiple sclerosis

Publications (2)

Publication Number Publication Date
CN102076326A CN102076326A (zh) 2011-05-25
CN102076326B true CN102076326B (zh) 2015-12-02

Family

ID=43352974

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980124930.5A Active CN102076326B (zh) 2008-04-28 2009-04-27 治疗多发性硬化的组合物和方法

Country Status (8)

Country Link
EP (1) EP2282719B1 (https=)
JP (2) JP5539965B2 (https=)
CN (1) CN102076326B (https=)
AU (1) AU2009241365B2 (https=)
BR (1) BRPI0911612A2 (https=)
CA (1) CA2722658C (https=)
MX (1) MX337862B (https=)
WO (1) WO2009134728A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8597689B2 (en) 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US8980325B2 (en) 2008-05-01 2015-03-17 Revalesio Corporation Compositions and methods for treating digestive disorders
CA2741336A1 (en) * 2008-10-22 2010-04-29 Revalesio Corporation Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
MX2012012634A (es) * 2010-04-30 2013-02-26 Revalesio Corp Métodos y composiciones para proteger contra agentes neurotóxicos.
BR112012028540A2 (pt) * 2010-05-07 2016-07-26 Revalesio Corp composições e métodos para melhorar desempenho fisiológico e tempo de recuperação
JP2013533320A (ja) * 2010-08-12 2013-08-22 レバレジオ コーポレイション タウオパチーを治療するための組成物および方法
US20120263764A1 (en) * 2011-04-13 2012-10-18 Revalesio Corporation Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease
CN103505731A (zh) * 2012-06-15 2014-01-15 中国药科大学 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
KR20240025721A (ko) * 2015-06-15 2024-02-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 노화와 연관된 질환을 치료하기 위한 방법 및 조성물
EP3456815B1 (en) * 2016-05-13 2024-07-03 SIGMA TECHNOLOGY, Inc. Aqueous solution capable of being administered to living body, and method for producing same
EP3843673B1 (en) * 2018-08-31 2026-04-15 Revalesio Corporation An oxygenated fluid for use for the treatment of stroke
EP3991746A4 (en) * 2019-06-26 2023-08-09 Takeda Pharmaceutical Company Limited TRANSFECTION METHOD
US11686208B2 (en) 2020-02-06 2023-06-27 Rolls-Royce Corporation Abrasive coating for high-temperature mechanical systems

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1499977A (zh) * 2001-02-01 2004-05-26 ��¡���ӹɷ����޹�˾ 组织超氧化的组合物和方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1157720A (ja) * 1996-11-07 1999-03-02 Honda Motor Co Ltd 電解機能水、その製造方法及び製造装置
US6386751B1 (en) 1997-10-24 2002-05-14 Diffusion Dynamics, Inc. Diffuser/emulsifier
US7654728B2 (en) * 1997-10-24 2010-02-02 Revalesio Corporation System and method for therapeutic application of dissolved oxygen
US6426066B1 (en) * 2000-01-12 2002-07-30 California Pacific Labs, Inc. Use of physiologically balanced, ionized, acidic solution in wound healing
PL365909A1 (en) 2000-02-21 2005-01-10 Astrazeneca Ab Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
US7396441B2 (en) * 2002-02-22 2008-07-08 Aqua Innovations, Inc. Flow-through oxygenator
US20030232114A1 (en) * 2002-06-13 2003-12-18 Nikola Dekleva Method for liquid enrichment with oxygen and applications of enriched liquids
AU2002321678A1 (en) * 2002-09-09 2004-03-29 Boros Béla Oxygen-enriched water, treated within a magnetic field and heavy water
NZ543102A (en) 2003-04-24 2008-12-24 Incyte Corp Aza spiro alkane derivatives as inhibitors of metalloproteases
JP4144669B2 (ja) * 2004-03-05 2008-09-03 独立行政法人産業技術総合研究所 ナノバブルの製造方法
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
CA2513350A1 (en) * 2005-03-02 2006-09-02 Sydney West Area Health Service Treatment for multiple sclerosis
WO2007087637A2 (en) 2006-01-26 2007-08-02 Washington State University Research Foundation Compositions and methods using matrix metalloproteinase (mmp) inhibitors for treating cognitive impairment characterized by persistent or sustained mmp expression and/or activity
WO2008018932A2 (en) * 2006-05-01 2008-02-14 The Board Of Trustees Of The Leland Stanford Junior University Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
JP5491185B2 (ja) * 2006-10-25 2014-05-14 リバルシオ コーポレイション 傷のケアおよび処置の方法
US8597689B2 (en) 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
AU2007308838B2 (en) 2006-10-25 2014-03-13 Revalesio Corporation Mixing device and output fluids of same
EP2215260A4 (en) * 2007-10-25 2011-04-20 Revalesio Corp COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION
CA2741336A1 (en) * 2008-10-22 2010-04-29 Revalesio Corporation Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1499977A (zh) * 2001-02-01 2004-05-26 ��¡���ӹɷ����޹�˾ 组织超氧化的组合物和方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Hypoxia-like tissue injury as a component of multiple sclerosis lesions.;LASSMANN;<J.NEUROL.SCI.>;20030215;第206卷(第2期);187-191 *
RUTGEERTS et al.Review article: the limitations of corticosteroid therapy in Crohn"s disease..<ALIMENT PHARMACOL THER>.2001,第15卷(第10期),1515-1525. *
VAN WINSEN，et al.Sensitivity to glucocorticoids is decreased in relapsing remitting multiple sclerosis.<J.CLIN.ENDOCRINOL.METAB>.2005,第90卷(第2期),734-740. *

Also Published As

Publication number Publication date
AU2009241365A1 (en) 2009-11-05
JP2014169307A (ja) 2014-09-18
WO2009134728A2 (en) 2009-11-05
CA2722658C (en) 2018-09-18
CN102076326A (zh) 2011-05-25
MX2010011846A (es) 2011-04-11
EP2282719A2 (en) 2011-02-16
CA2722658A1 (en) 2009-11-05
JP5869612B2 (ja) 2016-02-24
WO2009134728A3 (en) 2010-01-21
JP5539965B2 (ja) 2014-07-02
AU2009241365B2 (en) 2015-01-22
EP2282719A4 (en) 2011-11-09
JP2011523627A (ja) 2011-08-18
BRPI0911612A2 (pt) 2015-12-15
MX337862B (es) 2016-03-16
EP2282719B1 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
CN102076326B (zh) 治疗多发性硬化的组合物和方法
US9745567B2 (en) Compositions and methods for treating multiple sclerosis
CN101909649B (zh) 用于治疗哮喘和其他肺病患的组合物和方法
CN101909648B (zh) 用于治疗炎症的组合物和方法
CN102076327B (zh) 治疗消化功能紊乱的组合物和方法
US9523090B2 (en) Compositions and methods for treating inflammation
US20100015235A1 (en) Compositions and methods for treating multiple sclerosis
US10125359B2 (en) Compositions and methods for treating inflammation
US20090274771A1 (en) Compositions and methods for treating asthma and other lung disorders
US20100008997A1 (en) Compositions and methods for treating asthma and other lung disorders
US20100004189A1 (en) Compositions and methods for treating cystic fibrosis
US20100303918A1 (en) Compositions and methods for treating asthma and other lung disorders
US20100303917A1 (en) Compositions and methods for treating cystic fibrosis
US20120114702A1 (en) Compositions and methods for treating asthma and other lung disorders
WO2010062628A1 (en) Compositions and methods for treating asthma and other lung disorders
WO2009055729A1 (en) Compositions and methods for treating inflammation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant